Leadership

Dr. Haber serves as Biomica’s Chief Executive Officer. Prior to joining Biomica Dr. Haber served as Therapix Biosciences (Nasdaq, TASE: TRPX) CEO leading the company to a successful IPO on Nasdaq and advancing the Company's programs to clinical stage.
Dr. Haber spent more than 10 years as Chairman and board member of several privately held, and publicly traded companies. Dr. Haber has served in senior executive roles in various life science companies and a private investment firm.
Dr. Haber holds a PhD in Pharmaceutical Science and an MBA in Finance & Financial Engineering, both from The Hebrew University of Jerusalem, Israel

Chief of the Gastroenterology and Hepatology Division of the Meir Medical Center in Israel; Adjunct Professor of Medicine at Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, USA

Prof. Ringel has more than 30 years of diverse experiences, especially in Gastroenterology and translational research, and is an expert on IBS and functional motility disorders; he serves as an editor and in editorial boards of prestigious Scientific Journals. Prof. Ringel is Recipient of several prestigious awards. He received his medical degree from Technion Institute of Technology, Israel.

Dr. Meshner spent over 5 years working in the pharma industry both in the US and in Israel (OSI pharmaceuticals and Teva pharmaceuticals) and previously served as the head & principal investigator of the Dead Sea microbiology lab in the Dead Sea-Arava Science Center.

Dr. Meshner holds a PhD in systems microbiology from the Department of Physics of Complex Systems at The Weizmann Institute.

Ms. Yifat Zommer serves as Biomica’s VP of Finance . Prior to joining Biomica, Ms. Zommer served as a finance advisor to public and private companies. Prior to that, Ms. Zommer served as Chief Financial Officer of Oramed Pharmaceuticals Inc. (NASDAQ, TASE: ORMP) from 2009 to 2017.
Ms. Zommer holds a Bachelor of Accounting and Economics degree from the Hebrew University, an MBA from Tel-Aviv University and a Masters degree in Law (LL.M.) from Bar-Ilan University, Israel, and is a certified public accountant.

Chief of the Gastroenterology and Hepatology Division of the Meir Medical Center in Israel; Adjunct Professor of Medicine at Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, USA
Prof. Ringel has more than 30 years of diverse experiences, especially in Gastroenterology and translational research, and is an expert on IBS and functional motility disorders; he serves as an editor and in editorial boards of prestigious Scientific Journals. Prof. Ringel is Recipient of several prestigious awards. He received his medical degree from Technion Institute of Technology, Israel.

Prof. Willem M De Vos is Professor and Chair of Microbiology at Wageningen University, the Netherlands and Professor of Human Microbiomics at the University of Helsinki, Finland, where he also served as Finland Distinguished and Academy Professor. He supervised over 100 PhD students, is a member of the Royal Netherlands Academy of Arts and Sciences, and various academic and industry boards. He has (co) authored over 700 peer-reviewed papers, was involved in the filing of more than 50 patents or patent applications., and received many international scientific, honorary and royal awards.

Prof. R. Balfour Sartor serves as the Midget Distinguished Professor of Medicine, Microbiology and Immunology and Director of the Multidisciplinary IBD Center at the University of North Carolina, Chapel Hill. In addition he has served, as Chief Medical Advisor to the Crohn's and Colitis Foundation, where he now directs the Litwin Pioneers grants program and is a nationally and internationally recognized authority on host- microbial interactions, mucosal immunology and inflammatory bowel diseases

Prof. James Versalovic, Pathologist-In-Chief at Texas Children’s Hospital and Director of Texas Children’s Microbiome Center, Professor and Vice Chair of Pathology & Immunology at Baylor College of Medicine, a Professor of Molecular and Human Genetics, Molecular Virology & Microbiology, and Pediatrics. Prof. Versalovic created the first pediatric microbiome center and the first therapeutic microbiology fellowship program in the US. He served as Editor-in-Chief of the Manual of Clinical Microbiology and has authored more than 160 primary manuscripts and received notable awards.

David T. Rubin, MD, is a renowned gastroenterologist who specializes in the treatment and assessment of digestive diseases. His clinical expertise includes inflammatory bowel diseases (Crohn’s disease and ulcerative colitis) and high-risk cancer syndromes.
Dr. Rubin performs clinical research related to outcomes in inflammatory bowel diseases, with particular interest in prevention of cancer associated with these gastrointestinal diseases. He is also interested in new therapies for inflammatory bowel diseases, better screening tools for colorectal cancer, and the genetics of inflammatory bowel diseases.

Prof. Gal Markel is an internationally recognized expert in translational tumor immunology and clinical immuno-oncology. Prof. Markel serves as the Director of the Davidoff Cancer Center & Deputy Director General of the Rabin Medical Center at Clalit Health Services in Israel. Prof. Markel is Professor of Tumor Immunology in the Faculty of Medicine at Tel-Aviv University. He is the author of more than 130 peer-reviewed papers and the inventor of more than 20 patents. Prof. Markel co-founded BTC (acquired by DSPG in 2011), was the scientific founder and Chief Scientific Officer of cCAM Biotherapeutics (acquired by Merck & Co in 2015) and 4C Biomed.

Dr. Ravid Straussman, is the Principle investigator of the Tumor microenvironment, tumor microbiome and resistance to anti-cancer therapy lab at the Weizmann Institute of Science, Israel. Straussman's lab focuses on understanding the roles of the tumor microenvironment and the tumor microbiome in resistance to cytotoxic, targeted, and immune mediated anti-cancer therapies. Straussman holds an MD/ PhD from the Hebrew University Hadassah Medical School and completed a Post-doc training at the Broad Institute of Harvard and MIT.